Media coverage
1
Media coverage
Title CastleVax Inc. Receives $34 Million from BARDA to Continue Advancing Intranasal NDV-based COVID-19 Vaccine into Phase 2b Clinical Efficacy Testing Media name/outlet Impact Financial News Country/Territory United Kingdom Date 31/07/24 Persons Florian Krammer, Peter Palese, Adolfo Garcia-Sastre, Weina Sun